These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
619 related articles for article (PubMed ID: 28024291)
1. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation. Zhu B; Zhang H; Yu L Biomed Pharmacother; 2017 Feb; 86():547-554. PubMed ID: 28024291 [TBL] [Abstract][Full Text] [Related]
2. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin. Zhang X; Li J; Yan M Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448 [TBL] [Abstract][Full Text] [Related]
3. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system. Wang L; Wang W; Rui Z; Zhou D Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy. Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296 [No Abstract] [Full Text] [Related]
5. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. Cui T; Zhang S; Sun H Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466 [TBL] [Abstract][Full Text] [Related]
6. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Hadinoto K; Sundaresan A; Cheow WS Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180 [TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer. Wang F; Li L; Liu B; Chen Z; Li C Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535 [TBL] [Abstract][Full Text] [Related]
8. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Han L; Huang R; Liu S; Huang S; Jiang C Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964 [TBL] [Abstract][Full Text] [Related]
9. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers. Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692 [TBL] [Abstract][Full Text] [Related]
10. Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance of cancer cells. Yuan Y; Chiba P; Cai T; Callaghan R; Bai L; Cole SPC; Cai Y Oncol Rep; 2018 Aug; 40(2):1055-1063. PubMed ID: 29901161 [TBL] [Abstract][Full Text] [Related]
11. Multifunctional Polyethylene Glycol (PEG)-Poly (Lactic-Co-Glycolic Acid) (PLGA)-Based Nanoparticles Loading Doxorubicin and Tetrahydrocurcumin for Combined Chemoradiotherapy of Glioma. Zhang X; Zhao L; Zhai G; Ji J; Liu A Med Sci Monit; 2019 Dec; 25():9737-9751. PubMed ID: 31856143 [TBL] [Abstract][Full Text] [Related]
12. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Cui Y; Xu Q; Chow PK; Wang D; Wang CH Biomaterials; 2013 Nov; 34(33):8511-20. PubMed ID: 23932498 [TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Li X; Ding L; Xu Y; Wang Y; Ping Q Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296 [TBL] [Abstract][Full Text] [Related]
14. Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. Pang Z; Gao H; Yu Y; Guo L; Chen J; Pan S; Ren J; Wen Z; Jiang X Bioconjug Chem; 2011 Jun; 22(6):1171-80. PubMed ID: 21528923 [TBL] [Abstract][Full Text] [Related]
15. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice. Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307 [TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle. Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184 [TBL] [Abstract][Full Text] [Related]
18. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells. Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762 [TBL] [Abstract][Full Text] [Related]
19. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Han Y; Zhang P; Chen Y; Sun J; Kong F Int J Mol Med; 2014 Jul; 34(1):191-6. PubMed ID: 24804644 [TBL] [Abstract][Full Text] [Related]
20. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]